grihanovveimavox.blogspot.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a divisiob of (NYSE:JNJ), makes the blockbuster rheumatoisd arthritis treatment Remicade, and had sued Abbotf over Abbott’s arthritis drug, Humira. Both are so-called anti-TNd arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusive licensese ofthe patent, which is co-ownec by . Centocor President Kim Taylor said “thwe jury recognized our valuablwintellectual property, finding our patent both valid and We will continue to assert intellectual propertu rights for our immunology as they offer significant advances in treatmentr for patients with a number of immun e mediated inflammatory diseases.
” Abbott spokesman Scotyt E. Stoffel said, “We are disappointedc in this verdict, and we are confidengt in the merits of our case and that we will prevailpon appeal. “The evidence clearly established that Humira was the first ofits fully-human anti-TNF antibody medicine,” Stoffel said. “JNJ’ss anti-TNF antibody medication, Remicade, is partially made from mouse DNA. JNJ did not launch a fully-humahn product until April 2009. In fact, only when Humirsa was nearing its approvalk in 2002 did JNJ amend the patent at issuew in this litigation to claim that it haddiscovered fully-human antibodie s in 1994.
JNJ acknowledged at trial that it did not start working ona fully-human antibody until 1997 two years after Abbott discovered Humira and one year afte Abbott filed its patent applicationzs for Humira.”
ไม่มีความคิดเห็น:
แสดงความคิดเห็น